MedWatch

Analysts agree: Kåre Schultz was the right man for Teva – for a time

An era has come to an end for Schultz, who will no longer be found leading the Israeli pharmaceutical firm in the New Year. Two analysts tell the story of reign, both the ups and the downs.

Kåre Schultz, outgoing CEO of Teva | Photo: Amir Cohen/Reuters/Ritzau Scanpix

”He was the right man at the right time, but it’s correct for him to no longer be there.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs